APOE and Alzheimer disease: As expected, ApoE4 carriers had an increased risk of developing probable (χ2 test: 30% versus 14%, p < 0.0001) or possible (χ2 test: 10% versus 8%, p = 0.01) AD compared with ApoE4 non-carriers (Table 1).